Browse by Phase
Phase 3 Clinical Trials
Phase 3 trials compare a new drug or treatment against the current standard of care in a large population (300–3,000+ participants). Successful Phase 3 results are the basis for regulatory approval.
Total Trials
88
Recruiting Now
88
Top Conditions in Phase 3
Frequently Asked Questions — Phase 3 Trials
Why are Phase 3 trials the standard for drug approval?
Phase 3 trials compare a new treatment against the current standard of care in a large, randomized population of 300–3,000+ participants. This large-scale comparative evidence is what regulatory agencies—FDA, EMA—require to approve a new drug. A successful Phase 3 trial demonstrates that the new treatment is more effective, safer, or both compared to existing options in a statistically significant, reproducible way.
What is a placebo control in a Phase 3 trial?
Many Phase 3 trials use a placebo control—a group that receives an inactive substance—to isolate the true effect of the treatment. When an established standard of care exists, control-arm participants typically receive that treatment rather than a placebo, for ethical reasons. Blinded designs prevent participants and investigators from knowing who received which treatment, reducing bias in outcome assessment.
How do I find and join a Phase 3 clinical trial?
ClinicalMetric lists all Phase 3 trials registered on ClinicalTrials.gov. Each trial card shows recruitment status, enrollment target, sponsor, conditions studied, and site locations. To join a Phase 3 trial, review the eligibility criteria and contact the trial site directly—usually an academic medical center or hospital. Your physician can facilitate a referral to the appropriate study site.
Active Phase 3 Studies
NCT04947059 Phase 3
Recruiting
Effectiveness of an Immediate Postoperative Intravesical Instillation With Eithe...
Condition
Bladder Cancer
Enrollment
180 pts
Location
Greece
Sponsor
University of Thessaly
NCT06383780 Phase 3
Recruiting
Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasophar...
Condition
Nasopharyngeal Carcinoma
Enrollment
90 pts
Location
China
Sponsor
XIANG YANQUN
NCT07366086 Phase 3
Recruiting
Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteoge...
Condition
Osteogenesis Imperfecta
Enrollment
71 pts
Location
United States, Germany, Japan
Sponsor
Amgen
NCT06866405 Phase 3
Recruiting
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vac...
Condition
RSV Infection
Enrollment
550 pts
Location
United States, Argentina, South Africa
Sponsor
Pfizer
NCT06551246 Phase 3
Recruiting
Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Day...
Condition
Urinary Incontinence in Children
Enrollment
236 pts
Location
Denmark
Sponsor
University of Aarhus
NCT06889688 Phase 3
Recruiting
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemoth...
Condition
Breast Cancer Stage IV
Enrollment
246 pts
Location
China
Sponsor
Sun Yat-Sen Memorial Hospital
NCT06794086 Phase 3
Recruiting
SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases
Condition
Colorectal Cancer
Enrollment
24 pts
Location
China
Sponsor
Jun Huang
NCT06278870 Phase 3
Recruiting
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ A...
Condition
HER2-positive Metastatic Breast Cancer
Enrollment
312 pts
Location
China
Sponsor
Sun Yat-Sen Memorial Hospital
NCT07170150 Phase 3
Recruiting
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer...
Condition
Alzheimers Disease
Enrollment
800 pts
Location
United States, Argentina, Australia
Sponsor
Hoffmann-La Roche
NCT07533123 Phase 3
Recruiting
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients ...
Condition
Triple Negative Breast Cancer
Enrollment
364 pts
Location
China
Sponsor
Jiangsu Alphamab Biopharmaceut
NCT06498479 Phase 3
Recruiting
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cel...
Condition
Small Cell Lung Cancer
Enrollment
460 pts
Location
China
Sponsor
Hansoh BioMedical R&D Company
NCT05624996 Phase 3
Recruiting
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for...
Condition
Locally Advanced Lung Non-Small Cell Carcinoma
Enrollment
474 pts
Location
United States, Canada
Sponsor
NRG Oncology
NCT02025023 Phase 3
Recruiting
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Com...
Condition
Chalazion
Enrollment
120 pts
Location
United States
Sponsor
University of Washington
NCT06953583 Phase 3
Recruiting
A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omavelo...
Condition
Friedreich Ataxia
Enrollment
255 pts
Location
United States, Australia, Austria
Sponsor
Biogen
NCT07238465 Phase 3
Recruiting
Exploring Sympathetic Nervous System Function in Individuals With Down Syndrome
Condition
Down Syndrome
Enrollment
200 pts
Location
United States
Sponsor
University of Colorado, Denver
NCT06517173 Phase 3
Recruiting
Y-3 for Injection in the Treatment of Acute Ischemic Stroke
Condition
Acute Ischemic Stroke
Enrollment
998 pts
Location
China
Sponsor
Beijing Tiantan Hospital
NCT07166094 Phase 3
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Inves...
Condition
Endometrial Cancer
Enrollment
660 pts
Location
United States, Australia, Belgium
Sponsor
Genmab
NCT06702553 Phase 3
Recruiting
Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmona...
Condition
Nitric Oxide
Enrollment
3,650 pts
Location
United States, China, Russia
Sponsor
Xijing Hospital
NCT05674994 Phase 3
Recruiting
Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopa...
Condition
Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Enrollment
110 pts
Location
France
Sponsor
Fondation Hôpital Saint-Joseph
NCT06747351 Phase 3
Recruiting
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyel...
Condition
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Enrollment
59 pts
Location
United States, Argentina, Czechia
Sponsor
Takeda
NCT04775381 Phase 3
Recruiting
Total Post-thyroidectomy Hypocalcemia After Preoperative Cholecalciferol Supplem...
Condition
Hypocalcemia
Enrollment
200 pts
Location
France
Sponsor
Hôpital NOVO
NCT04521881 Phase 3
Recruiting
Clinical Randomisation of an Anti-fibrinolytic in Symptomatic Mild Head Injury i...
Condition
Traumatic Brain Injury
Enrollment
5,000 pts
Location
United Kingdom
Sponsor
London School of Hygiene and T
NCT06421870 Phase 3
Recruiting
Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney...
Condition
Chronic Kidney Diseases
Enrollment
210 pts
Location
Egypt
Sponsor
Ain Shams University
NCT06229483 Phase 3
Recruiting
The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Crani...
Condition
Brain Tumor
Enrollment
102 pts
Location
Canada
Sponsor
Stephen Lownie
NCT06829472 Phase 3
Recruiting
Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study o...
Condition
Toxicities
Enrollment
120 pts
Location
China
Sponsor
Shanghai Jiao Tong University
Page 1 of 4 — 88 trials total
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology